Navigation Links
Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists

SWEDESBORO, N.J., Jan. 21 /PRNewswire/ -- Wedgewood Pharmacy has announced that it will continue to provide Avastin(R) (Bevacizumab) to retinal specialists and ophthalmologists who request it for their patients. The announcement responds to Avastin's manufacturer, Genentech's, decision ( to stop supplying Avastin directly to compounding pharmacies as of January 1.

Avastin is commonly administered by retinal specialists and ophthalmologists to treat age-related wet macular-degeneration, a leading cause of blindness in the elderly. Although regulators haven't authorized Avastin's use against eye disease, it is chemically similar to Genentech's new product, Lucentis(R), which is about 50 times as costly as Avastin. On prescriptive authority of physicians, compounding pharmacies prepare, under sterile laboratory conditions, a once-monthly dose of the drug for use in the eye that costs about $40.

At Wedgewood, technicians trained in aseptic technique prepare Avastin 25mg/ml in individual syringes in a Class-1000 clean room under a Class-100 laminar-flow hood to assure sterility and quality.

"Many retinal specialists consider the Avastin treatment option as an indispensable part of their practices," said George Malmberg, RPH, FACA, FACVP the pharmacist president and CEO of Wedgewood Pharmacy. "We will continue to meet the critical and ongoing need for Avastin in ophthalmologic practice. Unlike other firms, we do not require that our customers make a long-term contractual agreement to purchase this vital medicine from us."

Avastin is an FDA-approved drug that is used in the treatment of metastatic colorectal cancer. Based on the pioneering work of Dr. Philip Rosenfeld, a professor of Ophthalmology at the world-renowned Bascom Palmer Eye Institute at the University of Miami, Miller School of Medicine, Avastin also has been used off-label by retinal specialists and ophthalmologists to treat thousands of patients with age-related macular degeneration (AMD), a disease that causes blindness.

About Wedgewood Pharmacy

A compounding pharmacy creates customized medications for individual patients in response to a licensed practitioner's prescription. Wedgewood Pharmacy is one of the largest compounding pharmacies in the United States, serving more than 20,000 prescribers of compounded medications. It is located in Swedesboro NJ and licensed throughout the United States.

Background: About Compounding Pharmacy

Because every patient is different and has different needs, customized, compounded medications are a vital part of quality medical care. The basis of the profession of pharmacy has always been the "triad," the patient- prescriber-pharmacist relationship. Through this relationship, patient needs are determined by a prescriber, who chooses a treatment regimen that may include a compounded medication. Prescribers often prescribe compounded medications for reasons that include (but are not limited to) the following situations:

-- When needed medications are discontinued by or generally unavailable

from pharmaceutical companies, often because the medications are no

longer profitable to manufacture;

-- When the patient is allergic to certain preservatives, dyes or binders

in available off-the shelf medications;

-- When treatment requires tailored dosage strengths for patients with

unique needs (for example, an infant);

-- When a pharmacist can combine several medications the patient is taking

to increase compliance;

-- When the patient cannot ingest the medication in its commercially

available form and a pharmacist can prepare the medication in cream,

liquid or other form that the patient can easily take; and

-- When medications require flavor additives to make them more palatable

for some patients.

For additional information, visit the International Academy of Compounding Pharmacists' Web site at and


Marcy Kelly

Vice President, Marketing


David Kirk, APR, Fellow PRSA


SOURCE Wedgewood Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
2. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
3. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
4. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
5. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
6. Good Neighbor Pharmacy Joins with Diversified Racing Solutions to Enter NASCAR Nationwide Series in 2008
7. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
8. Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits
9. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
10. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
Post Your Comments:
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
Breaking Biology News(10 mins):